Case reports
Dermatitis due to mitomycin bladder instillations' V S Neild MB MRCP K V Sanderson FRCP FRACP P R Riddle MS FRCS St George's Hospital, London SWJ7 OQT A patient is reported who developed severe vesicular palmo-plantar eczema during the course of bladder instillations with mitomycin-C and was subsequently shown to have positive patch tests to this substance. Intravesical mitomycin-C, when used in the management of superficial papillary transitional cell carcinoma of the bladder, has been associated with no significant systemic toxicity but occasional bladder irritation and hand rashes have been previously reported. The mechanism by which sensitization to this drug may have occurred in this case is discussed.
Case report
Mr E W, who is 75 years old, first presented in 1970 with haematuria due to multifocal superficial papillary transitional cell carcinoma of the bladder. He was treated initially by endoscopic resection, the tumours at that time being entirely superficial. However, by 1981 recurrences were more numerous and invaded the basement membrane of the urothelium. At this time the grade of the tumour had worsened: GIII-Plb (WHO classification). In April 1982 a course of mitomycin-C bladder instillations was commenced in which 30 mg mitomycin in 30 ml normal saline was instilled into the bladder for 2 hours; this was repeated weekly for the next 6 weeks and subsequently on alternate weeks. After the fifth instillation he complained of irritation of the palms and soles. The irritation apparently started within hours of the instillation and lasted for increasing periods of time after each treatment. A burning discomfort in the lower abdomen following each treatment was the only other symptom noted. Following his eighth treatment the patient not only developed irritation, but also acute vesicular eczema of the palms and particularly the soles of his feet. Mitomycin was stopped and the eczema resolved slowly over the next month.
On examination, he was a healthy man with Case presented to Section of Dermatology, 19 May 1983. Accepted 29 March 1984 signs of resolving vesicular eczema on the soles and palms, the skin being otherwise normal.
Mycology scrapings were negative. Patch tests were performed with the International Contact Dermatitis Research Group standard series (with lignocaine added) and to 0.1% mitomycin in soft yellow paraffin. Results were negative at 2 and 4 days except for a positive + +reaction to the mitomycin present at both 2 and 4 days. Ten controls tested at the time to the same dilution of mitomycin were all negative, including 2 other patients treated with mitomycin instillations for carcinoma of the bladder. Patch testing with serial dilutions of mitomycin in our patient were later shown to be positive down to a dilution of 0.001% in yellow soft paraffin.
The patient has remained remarkably clear of tumour growth since 1982, his profound sensitivity to the drug possibly having enhanced its clinical effect.
Discussion
Mitomycin is an alkylating agent producing interstrand and intra-strand DNA cross-links, thus inhibiting DNA synthesis. It is an aminoquinone with a molecular weight of 334 and broadspectrum antitumour activity. Though it is a myelosuppressant drug when used systemically, no significant systemic absorption or systemic toxicity has been demonstrated after its use intravesically (Mishina et al. 1975) . De Furia et al. in 1980 did report a 5% incidence of rash on the hands in their multicentre study of 63 patients receiving mitomycin therapy, and thought that this was probably an allergic reaction.
Cutaneous sensitivity to an agent usually develops following epidermal sensitization. Once this has occurred, subsequent systemic exposure can cause dermatitis and/or systemic symptoms to arise. In general, mucosae are both more resistant to primary irritants and not easily sensitized. Sensitized mucosae previously recorded include the mouth (metals used in dentistry, toothpastes and mouthwashes), rectum, penis and vulva (contraceptives, medicaments and cleansing agents) (Fisher 1973) .
Our patient may have developed primary sensitization to mitomycin-C by accidental contamination of the skin whilst being catheterized or on voiding the mitomycin instillation, further symptoms being produced on subsequent exposure, either after systemic absorption of the drug via the urethra (during catheterization) or via the bladder during the period of instillation.
Journal of the Royal Society of Medicine Volume 77 July 1984 611 Alternatively, it is possible that primary sensitization may have occurred directly across the transitional cell epithelium of his bladder, the mitomycin causing local bladder irritation followed by skin symptoms, namely pruritus and eczema of the feet and hands. The Langerhans' cell is currently held to be important in sensitizing reactions as an antigen-presenting cell, and it is interesting to speculate (though not yet proven) that similar cells may be present among the transitional cell epithelial lining of the bladder as well as in the keratinized squamous epithelium of the skin. Most reported cases of metallic mercury poisoning are of accidental origin, but suicidal attempts have been reported (Conrad et al. 1957 , Schulze 1958 , Johnson & Koumides 1967 , Umber 1923 . Intravenous injection of metallic mercury may lead to widespread dissemination and death. Persistent exposure to metallic mercury and its salts may lead to long-term complications (Hunter 1978) . A case is reported of unexplained perivenous metallic mercury deposits, treated by excision of the affected skin, which were not accompanied by any symptoms of mercury intoxication. However, the very high serum and urinary levels of mercury clearly showed that metallic mercury is far from an inert material and should, wherever possible, be removed without delay.
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Case report
A 23-year-old married Indian woman, who had lived in the UK for seven years, presented in the Accident and Emergency Department with an 'inflammation' on the front of her right 'elbow'. This had first been noted about ten days before by the Industrial Medical Officer of the food factory where she worked. In the right antecubital fossa there were seven discrete raised and thickened areas of skin, up to 1 cm diameter, slightly tender and resembling indolent or 'blind' boils. The intervening and surrounding skin was tender to touch and felt indurated, and the whole of this strange lesion followed the oblique course of the underlying antecubital vein. The woman, who spoke adequate English, denied any interference with her arm and said the lumps had appeared about two weeks earlier. However, she looked quite concerned and worried. On the premise that this might be a little 'do-it-yourself' tattooing leading to cellulitis and even superficial thrombophlebitis, oral antibiotics were prescribed (fiucloxacillin 250 mg 6 hourly).
A week later there was no significant change in appearance but one lump felt fluctuent. Hoping to get either pus for culture or a biopsy, this lump was incised under local anaesthesia and produced an unusual salmon-pink coloured sero-pus; a hand lens demonstrated minute globules of what could only be metallic mercury. Laboratory examination confirmed this and showed no growth on culture. Other investigations included normal blood sugar (4.1 mmol/l), haemoglobin (12.8 g/dl) and white cell count (8.7 x 109/1), but the erythrocyte sedimentation rate was 61 mm in the first hour. The urine contained no sugar or protein and no organisms were detected. X-ray examination of the forearm showed innumerable globules of metallic opacity in varying sizes arranged in a line crossing obliquely the front of the elbow joint from side to side and tending to run up the medial aspect of the upper arm ( Figure IA) . The distribution strongly suggested perivenous deposits around the antecubital vein. On examining these X-rays together with the patient and her husband, both firmly denied any knowledge of how the mercury came to be there.
A chest X-ray showed no sign of pulmonary globules of mercury, but her blood mercury level was 345 gg/l and a 24-hour urine for mercury output showed 1688 jg/l. Blood levels usually show no detectable mercury and the urinary output is normally less than 30 gg/l. The serum creatinine was 70 mmol/l (normal 40-130 mmol/l).
An attempt was made to remove the mercury by further incisions under the X-ray image intensifier, but the globules were so minute and so widely distributed in the intercellular spaces that it became clear that only by excision of the affected skin could the mercury be removed. The patient was admitted to hospital and treatment with penicillamine 125 mg twice daily by mouth began. We were advised that N-acetyl-D-penicilla-1Accepted 14 March 1984 2Present address: Hammersmith Hospital, London W6 0141-0768/84/07061 1-03/$01.00/0
